Viatris (VTRS) Cost of Revenue (2020 - 2026)
Viatris (VTRS) posted Cost of Revenue of $2.3 billion for Q2 2026, down 2.52% on a QoQ basis from $2.4 billion in Q1 2026, and up 2.27% year-over-year from $2.2 billion in Q2 2025.
Analysis
Viatris (VTRS) Cost of Revenue (2020 - 2026) Analysis & Trends
Viatris has reported Cost of Revenue for 7 years, with the latest figure at $2.3 billion in Q2 2026.
- On a quarterly basis, Cost of Revenue rose 2.27% year-over-year to $2.3 billion in Q2 2026; TTM through Jun 2026 was $9.6 billion, a 7.34% increase from a year earlier, with the FY2025 full-year figure at $9.3 billion, up 1.87% from the prior year.
- Cost of Revenue was $2.3 billion for Q2 2026 at Viatris, down from $2.4 billion in the prior quarter.
- The five-year high for Cost of Revenue was $2.6 billion in Q4 2022, with the low at $2.1 billion in Q1 2025.
- Average Cost of Revenue over 5 years is $2.3 billion, with a median of $2.3 billion recorded in 2023.
- The sharpest annual moves came in 2022 and 2026: Cost of Revenue retreated 26.72% in 2022, then advanced 12.74% in 2026.
- Over 5 years, Cost of Revenue stood at $2.6 billion in 2022, then slipped by 13.88% to $2.2 billion in 2023, then advanced by 3.23% to $2.3 billion in 2024, then increased by 10.49% to $2.6 billion in 2025, then retreated by 9.99% to $2.3 billion in 2026.
- The last three Cost of Revenue figures came in at $2.3 billion (Q2 2026), $2.4 billion (Q1 2026), and $2.6 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.56 Bn | 38.90 Bn | 2.15 Bn | 1.99 Bn |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | 2.30 Bn |
| 3 | Dr Reddys Laboratories | 9.86 Bn | 9.69 Bn | 396.53 Mn | 455.94 Mn |
| 4 | Amneal Pharmaceuticals | 5.46 Bn | 5.33 Bn | 334.51 Mn | 461.69 Mn |
| 5 | Bausch Health Companies | 2.37 Bn | 528.25 Mn | 2.10 Bn | 753.00 Mn |
| 6 | Alvotech | 1.51 Bn | 1.37 Bn | 2.56 Mn | 52.20 Mn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 100.16 Mn |
| 8 | Amphastar Pharmaceuticals | 992.90 Mn | 702.78 Mn | 93.47 Mn | 90.43 Mn |
| 9 | Fennec Pharmaceuticals | 411.43 Mn | 370.18 Mn | 17.15 Mn | 721,000.00 |
| 10 | RedHill Biopharma | 181.39 Mn | 181.39 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.30 Bn |
| Mar 31, 2026 | 2.36 Bn |
| Dec 31, 2025 | 2.56 Bn |
| Sep 30, 2025 | 2.39 Bn |
| Jun 30, 2025 | 2.25 Bn |
| Mar 31, 2025 | 2.09 Bn |
| Dec 31, 2024 | 2.31 Bn |
| Sep 30, 2024 | 2.29 Bn |
| Jun 30, 2024 | 2.35 Bn |
| Mar 31, 2024 | 2.16 Bn |
| Dec 31, 2023 | 2.24 Bn |
| Sep 30, 2023 | 2.25 Bn |
| Jun 30, 2023 | 2.31 Bn |
| Mar 31, 2023 | 2.19 Bn |
| Dec 31, 2022 | 2.60 Bn |
| Sep 30, 2022 | 2.33 Bn |
| Jun 30, 2022 | 2.41 Bn |
| Mar 31, 2022 | 2.42 Bn |
| Dec 31, 2021 | 2.80 Bn |
| Sep 30, 2021 | 2.96 Bn |